The effectiveness of KYA1797K in the cetuximab-resistant CRC cells harboring KRAS mutations was also tested in vivo using a xenograft mouse model that produced tumors after the implantation of D-MT cells harboring both APC and KRAS mutations. The gene discussed is KRAS; the disease is colorectal carcinoma.